Therefore, the purpose of the present study was to evaluate the differential effect of imatinib and nilotinib on p53 gene serum levels in patients with chronic myeloid leukemia. The gene discussed is TP53; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.